Christopher J. John McDougle

Dr. Christopher J. John McDougle


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2016 in Molecular Autism
Verified
Journal Article
Open access
PDF file
LWLogan K. Wink
Logan K. Wink
RARyan Adams
Ryan Adams
ZWZemin Wang
Zemin Wang
JAMES Edward KLAUNIGJAMES Edward KLAUNIG
JAMES Edward KLAUNIG
MPMARTIN PLAWECKI
MARTIN PLAWECKI
CECraig A. Erickson
Craig A. Erickson
Social impairment is a defining feature of autism spectrum disorder (ASD) with no demonstrated effective pharmacologic treatments. The goal of this study was to evaluate efficacy, safety, and tolerability of oral N-acetylcysteine (NAC), an antioxidant whose function overlaps with proposed mechanisms of ASD pathophysiology, targeting core social impairment in youth with ASD. This study was a 12-week randomized, double-blind, placebo-controlled trial of oral NAC in youth with ASD. Study participants were medically healthy youth age 4 to 12 years with ASD, weighing ≥15 kg, and judged to be moderately ill based on the Clinical Global Impressions Severity scale. The participants were randomized via computer to active drug or placebo in a 1:1 ratio, with the target dose of NAC being 60 mg/kg/day in three divided doses. The primary outcome measure of efficacy was the Clinical Global Impressions Improvement (CGI-I) scale anchored to core social impairment. To investigate the impact of NAC on oxidative stress markers in peripheral blood, venous blood samples were collected at screen and week 12. Thirty-one patients were enrolled (NAC = 16, placebo = 15). Three participants were lost to follow-up, and three left the trial due to adverse effects. The average daily dose of NAC at week 12 was 56.2 mg/kg (SD = 9.7) with dose ranging from 33.6 to 64.3 mg/kg. The frequency of adverse events was so low that comparisons between groups could not be conducted. At week 12, there was no statistically significant difference between the NAC and placebo groups on the CGI-I (p > 0.69) but the glutathione (GSH) level in blood was significantly higher in the NAC group (p < 0.05). The oxidative glutathione disulfide (GSSG) level increased in the NAC group, however only at a trend level of significance (p = 0.09). There was no significant difference between the NAC and placebo groups in the GSH/GSSG ratio, DNA strand break and oxidative damage, and blood homocysteine levels at week 12 (ps > 0.16). The results of this trial indicate that NAC treatment was well tolerated, had the expected effect of boosting GSH production, but had no significant impact on social impairment in youth with ASD. Clinicaltrails.gov NCT00453180

26 October 2016 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
MMMaria Mody
Maria Mody
ASA. M. Shui
A. M. Shui
LNL. A. Nowinski
L. A. Nowinski
SGS. B. Golas
S. B. Golas
CFC. Ferrone
C. Ferrone
CMChristopher J. John McDougle
Christopher J. John McDougle

7 January 2025 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MMMariah A. Manter
Mariah A. Manter
KBKirstin B. Birtwell
Kirstin B. Birtwell
JBJames Bath
James Bath
NFNora D. B. Friedman
Nora D. B. Friedman
CKChristopher J. Keary
Christopher J. Keary
CMChristopher J. John McDougle
Christopher J. John McDougle
The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings. This work aims to empower healthcare providers, especially primary care providers (PCPs), with guidelines for the recognition and safe pharmacologic management of common co-occurring psychiatric and behavioral conditions in ASD. Lurie Center for Autism medical providers, who have extensive experience in ASD care, delineated approaches for recognition and pharmacological treatment of sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability tailored to ASD patients. Pharmacological guidelines were iteratively refined until consensus was reached. Treatment differences relative to standard of care (SOC) of non-autistic individuals are noted. Key literature and clinical trial results were reviewed to supplement clinical experience. The pharmacological treatment pathways reflect how appropriate medication options for ASD patients can depend on many factors unique to the patient and can differ from established non-autistic SOC. Key takeaways include: For sleep disturbances in ASD, initial strategies align with non-autistic SOC, emphasizing sleep hygiene and melatonin use. First-line recommendations for treating ADHD, anxiety, and depression in ASD differ from non-autistic SOC; α2-adrenergic agonists are more suitable than stimulants for some ASD-ADHD patients, buspirone and mirtazapine are preferred to selective serotonin reuptake inhibitors (SSRIs) for anxiety, and duloxetine, mirtazapine, bupropion, and vortioxetine are recommended ahead of SSRIs for depression. Addressing irritability in ASD requires interdisciplinary evaluation of contributing factors, and guanfacine, risperidone, or aripiprazole may be appropriate, depending on severity. Recognition and treatment of co-occurring psychiatric and behavioral conditions in autistic patients must account for differences in clinical presentation and medication effectiveness and tolerability. Drawing on evidence-based clinical insights, these guidelines seek to support PCPs in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD.

14 January 2016 in Molecular Autism
Verified
Journal Article
Open access
PDF file
NMNoha F. Minshawi
Noha F. Minshawi
LWLogan K. Wink
Logan K. Wink
RSRebecca Shaffer
Rebecca Shaffer
MPMARTIN PLAWECKI
MARTIN PLAWECKI
DPDavid J. Posey
David J. Posey
CECraig A. Erickson
Craig A. Erickson
Researchers have demonstrated that d-cycloserine (DCS) can enhance the effects of behavioral interventions in adults with anxiety and enhances prosocial behavior in animal models of autism spectrum disorders (ASD). This study extended upon this background by combining DCS with behavioral social skills therapy in youth with ASD to assess its impact on the core social deficits of ASD. We hypothesized that DCS used in combination with social skills training would enhance the acquisition of social skills in children with ASD. A 10-week, double-blind, placebo-controlled trial of DCS (50 mg) given 30 min prior to weekly group social skills training was conducted at two sites. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1:1 ratio. No statistically significant difference attributable to drug treatment was observed in the change scores for the primary outcome measure, the Social Responsiveness Scale (SRS), total score (p = 0.45), or on secondary outcome measures. The results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD. This suggests a need to further study the efficacy of the social skills training protocol. Limitations to the current study and areas for future research are discussed. ClinicalTrials.gov NCT01086475

30 January 2015 in Current Treatment Options in Psychiatry
Verified
Journal Article
Closed access
PDF file
LPLaura C. Politte
Laura C. Politte
YHYamini Howe
Yamini Howe
LNLisa Nowinski
Lisa Nowinski
MPMichelle Palumbo
Michelle Palumbo
CMChristopher J. John McDougle
Christopher J. John McDougle

17 December 2019 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
SMSun Jae Moon
Sun Jae Moon
JHJinseub Hwang
Jinseub Hwang
HHHarrison Scott Hill
Harrison Scott Hill
RKRyan Kervin
Ryan Kervin
KBKirstin Brown Birtwell
Kirstin Brown Birtwell
JKJunhyoung Kim
Junhyoung Kim
Objective The current study was performed to assess the evidence for effects of therapeutic intervention with mobile device applications (apps) for individuals with autism spectrum disorder (ASD). Design The main methodology of the current study was systematic review with meta-analysis. Setting Only randomised controlled trials (RCTs) for mobile device apps for individuals with ASD were considered for review in the current study. Patients The target population was individuals clinically diagnosed with ASD. Interventions Applications that are operable on a smart (mobile) device and interactive with users. Main outcome measures The main outcomes were based on standardised mean differences in pretrial and post-trial scales in each control and intervention group. Results Out of a total of 1100 studies (after duplicate removal), 7 RCTs were selected for final analysis. Of the seven studies, two RCTs were further analysed for effects based on the visual and fine motor subscales of the Mullen Scales of Early Learning, which favoured the intervention groups (standardised mean difference (SMD)=0.41, 95% CI 0.03 to 0.80; SMD=0.41, 95% CI 0.03 to 0.80), without either having any heterogeneity (p>0.1) or publication bias. Conclusions Although it is still early to draw a conclusion, available studies are showing promise for use of mobile device apps for treatment of individuals with ASD. More well-designed and large-scale studies focused on improving behavioural symptoms of ASD are warranted. PROSPERO registration number CRD42019128362.